Immunotherapy with mannan-MUC1 and IL-12 in MUC1 transgenic mice.
Mice immunised with oxidised mannan-MUC1 fusion protein (M-FP) develop MHC restricted CD8(+) cytotoxic T cells. We now demonstrate that in MUC1/HLA-A2 transgenic mice, IL-12 gives enhanced CTL, CTLp and tumor protection. CTLp in MUC1 transgenic mice with M-FP were 1/55,000, and with IL-12, this increased to 1/19,000, with improved tumor protection. Thus, IL-12 is important for effective CTL responses to MUC1 in transgenic mice.
The Austin Research Institute, Studley Rd, Heidelberg 3084, Victoria, Australia.
C J
CJ
Lees
V
V
Apostolopoulos
B
B
Acres
I
I
Ramshaw
A
A
Ramsay
C S
CS
Ong
I F
IF
McKenzie
D000818:Animals; D015789:HLA-A2 Antigen / Q000502:physiology; D007114:Immunization; D018664:Interleukin-12 / Q000627:therapeutic use*; D008351:Mannans / Q000276:immunology*; D051379:Mice; D008807:Mice, Inbred BALB C; D008811:Mice, Inbred DBA; D008822:Mice, Transgenic; D018396:Mucin-1 / Q000276:immunology*; D009374:Neoplasms, Experimental / Q000628:therapy*; D011993:Recombinant Fusion Proteins / Q000276:immunology*; D013602:T-Lymphocytes, Cytotoxic / Q000276:immunology
D015789:HLA-A2 Antigen; D008351:Mannans; D018396:Mucin-1; D011993:Recombinant Fusion Proteins; D018664:Interleukin-12